Kodiak Sciences Inc.
KODHeld by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (Tarcocimab tedromer): Aug 2026. Short interest: 26.6% of float.
Held by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (Tarcocimab tedromer): Aug 2026. Short interest: 26.6% of float.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.